Lawrence P. Guiheen is Director at ADMA BIOLOGICS, INC. (ADMA). They have made 8 open-market trades across 1 company since 2013, most recently 2026-03-17.
CIK 0001554353
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $316K since 2013, against 3 sales. Across 5 scored buys the stock is down 0.5% at ninety days, and 0.9 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ADMA | 30,000 | $321K |
Shares reported on the most recent Form 4, priced at the 2026-03-17 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 0% | 20% |
| Avg Move | -10.1% | -13.9% | -0.5% |
| Alpha | -5.8% | -9.7% | +0.9% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMA | SELL | 2025-06-09 | 2025-06-11 | $20.96 | $419K | -18.6% | -15.6% | -25.3% |
| ADMA | SELL | 2025-05-21 | 2025-05-23 | $20.31 | $341K | -2.5% | -12.6% | -16.4% |
| ADMA | SELL | 2024-09-09 | 2024-09-11 | $18.47 | $166K | +18.0% | +1.0% | +13.2% |
| ADMA | BUY | 2020-02-11 | 2020-02-11 | $3.50 | $70K | -7.9% | -42.4% | -29.7% |
| ADMA | BUY | 2019-05-17 | 2019-05-21 | $4.00 | $100K | -5.6% | -18.0% | -7.9% |
| ADMA | BUY | 2018-06-08 | 2018-06-11 | $4.78 | $96K | +3.6% | -6.2% | +38.2% |
| ADMA | BUY | 2015-03-16 | 2015-03-18 | $7.96 | $8K | -20.4% | -1.5% | -1.5% |
| ADMA | BUY | 2013-10-22 | 2013-10-23 | $8.50 | $43K | -20.4% | -1.5% | -1.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.